The clinical efficacy of gabapentin

Reviews in Contemporary Pharmacotherapy

Volumn 7, Issue 5, 1996, Pages 215-225

  Crawford, P M ^a  

^a YORK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000228186     PISSN: 09548602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Abou-Khalil B, McLean M, Castro I, Courville K. Gabapentin in the treatment of refractory partial seizures. Epilepsia 1990; 31: 644.
2. Abou-Khalil B, Shellenberger MK, Anhut H. Two open-label multicenter studies of the safety and efficacy of gabapentin in patients with refractory epilepsy. Epilepsia 1992; 33 (Suppl 3): 77.
3. Anhut H, Ashman P, Feuerstein TJ et al. Gabapentin as add-on therapy in patients with partial seizures: a double-blind placebo controlled study. Epilepsia 1994; 35: 795-801.
4. Anhut H, Griener M, Mockel V et al. Gabapentin as monotherapy in newly-diagnosed patients with partial epilepsy. Epilepsia 1995; 36 (Suppl 3): 119.
5. Bauer G, Bechinger D, Castell M et al. Gabapentin in the treatment of drug-resistant epileptic patients. Adv Epileptol 1989; 17: 219-221.
6. Betts T, Smith K. Audit of two years experience with gabapentin in an epilepsy clinic. Epilepsia 1995; 3 (Suppl 3): S120.
7. Browne TR, for the International, UK and US Gabapentin Study Groups. Efficacy and safety of gabapentin. In: Chadwick D, ed. New trends in epilepsy management: the role of gabapentin. London: Royal Society of Medicine, 1993: 47-57.
8. Bruni J, Saunders M, Anhut H, Sauermann W. Efficacy and safety of gabapentin (Neurontin): a multicenter, placebo-controlled, double-blind study. Neurology 1991; 41 (Suppl 1): 330-331.
9. Chadwick D. Gabapentin. Lancet 1994; 343: 89-91.
10. Crawford P, Ghadualis E, Lane R, Blumhardt, L, Chadwick D. Gabapentin as an epileptic drug in man. J Neurol Neurosurg Psychiatry 1987; 50: 682-686.
11. Foot M, Wallace J. Gabapentin. Epilepsy Res 1991; Suppl 3: 109-114.
12. Garofalo E, Hayes A, Greeley C et al. Gabapentin monotherapy in patients with medically refractory partial seizures: an open label extension study. Epilepsia 1995; 36 (Suppl 3): S119-S120.
13. Goa KL, Sorkin EM. Gabapentin: a review of its pharmacological properties and clinical potential in epilepsy. Drugs 1993; 46: 409-427.
14. Goodridge DMG, Shorvon SD. Epileptic seizures in a population of 6000. I. Demography, diagnosis and classification and role of the hospital services. Br Med J 1983a; 287: 641-644.
15. Goodridge DMG, Shorvon SD. Epileptic seizures in a population of 6000. II Treatment and prognosis. Br Med J 1983b; 287: 1020.
16. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 1993; 34: 453-468.
17. Hayes A, Garofalo E, Mann M et al. Quality of life assessments during a double-blind study of gabapentin in patients with medically refractory partial seizures. Epilepsia 1995; 36 (Suppl 3): S187.
18. Leiderman DB. Gabapentin as add-on therapy for refractory partial epilepsy: results of five placebo-controlled trials. Epilepsia 1994; 35 (Suppl 5) S74-S76.
19. Leppik IE, Shellenberger MK, Anhut H. Two open-label multicenter studies of the safety and efficacy of gabapentin as add-on therapy in patients with refractory partial seizures. Epilepsia 1992; 33 (Suppl 3): 117.
20. McLean MJ. Gabapentin. Epilepsia 1995; 36 (Suppl 2): S73-S86.
21. Miller AA, Sawuer DA, Roth B et al. Lamotrigine. In: Meldrum BS, Porter RJ, eds. New anticonvulsant drugs. London: John Libbey, 1986: 165-178.
22. Morris GL. Efficacy and tolerability of gabapentin in clinical practice. Clin Therapeut 1995; 17: 891-900.
23. Ojemann LM, Wilensky AJ, Temkin NR et al. Long-term treatment with gabapentin for partial epilepsy. Epilepsy Res 1992; 13: 159-165.
24. Parke-Davis. Neurontin product monograph. Eastleigh: Parke Davis, 1993: D7.
25. Ramsay RE, Wallace J, Shellenberger K, Wibberg M. Efficacy and safety of gabapentin (Neurontin) as add-on therapy in patients with uncontrolled partial seizures. Neurology 1991; 41 (Suppl 1): 380.
26. Schear MI, Weiner JA, Rowan AJ. Long-term efficacy of gabapentin in the treatment of partial seizures. Epilepsia 1991; 32 (Suppl 3): 6.
27. Schmidt B. Gabapentin. In: Levy R, ed. Antiepileptic drugs. Vol 3. New York: Raven Press, 1989: 925-935.
28. Shorvon S. The drug treatment of epilepsy. In: Hopkins A, Shorvon S, Cascino G, eds. Epilepsy. London: Chapman and Hall, 1995: 171-214.
29. Sivenius J, Kalviainen R, Ylinen A, Riekkinen P. Double-blind study of gabapentin in the treatment of partial seizures. Epilepsia 1991; 32: 539-542.
30. Taylor CP. Mechanisms of action of new antiepileptic drugs. In: Chadwick D, ed. New trends in epilepsy management: the role of gabapentin. London: Royal Society of Medicine, 1993: 13-40.
31. UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet 1990; 335: 1114-1117.
32. US Gabapentin Study Group No. 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind placebo-controlled parallel-group study. Neurology 1993; 43: 2292-2298.
33. US Gabapentin Study Group. The long-term safety and efficacy of gabapentin as add-on therapy in drug-resistant partial epilepsy. Epilepsy Res 1994; 18: 67-73.
34. Wong KS, Kay R. Gabapentin in the treatment of partial epilepsy in Chinese patients. Epilepsia 1995; 36: S120.